靶向 CD19、CD20 和 CD22 的床旁制备三特异性 CAR-T 细胞首次人体试验的安全性与临床结局

Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.

双特异性抗体治疗失败后复发/难治性弥漫大 B 细胞淋巴瘤 CAR-T 细胞挽救治疗的疗效与安全性分析

Efficacy and safety analysis of CAR-T cell salvage therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody t

CAR-T 挽救治疗在 BsAb R/R DLBCL 患者中显示出高缓解率和可控的安全性。早期生存数据表明，在这一 BsAb 耐药的高危人群中具有令人鼓舞的临床获益，尽管需要延长随访以确认持久性。本研究为 CAR-T 作为该情境下的一种潜在挽救策略提供了支持性证据。

在靶点选择指导下，inotuzumab ozogamicin 成功挽救一例抗 CD19 和抗 CD22 CAR-T 细胞治疗后的难治性滤泡性淋巴瘤患者：病例报告与文献综述

Guided by target selection, inotuzumab ozogamicin successfully salvaged a patient with refractory follicular lymphoma after anti-CD19 and anti-CD22 CA

CD19 CAR-T 细胞治疗后出现具有交叉抗原耐药和可预测临床 CAR-T 细胞反应基因特征的 DLBCL 细胞

DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response.

B 细胞淋巴瘤中 CAR-T 细胞治疗后复发的治疗策略

Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.

淋巴瘤的 CAR-T 细胞治疗：新场景与未来方向

Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.

其 5'-UTR 的可变剪接限制了 CD20 mRNA 翻译，并导致对 CD20 靶向免疫治疗的耐药性

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.

大 B 细胞淋巴瘤的 CAR-T 细胞疗法

CAR-T Cell Therapy in Large B Cell Lymphoma.

其 5'-UTR 的可变剪接限制 CD20 mRNA 翻译并导致对 CD20 靶向免疫治疗的耐药

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.

B 细胞恶性肿瘤新型治疗药物的现状：下一步是什么？

Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?